CDX
SK-OV-3
Tumor indication
Ovarian, Fallopian Tube
Tumor subtype
Serous carcinoma of the ovary
Description
SK-OV-3 (Ovarian Cancer CDX Model)
The SK-OV-3 ovarian cancer line was derived from an ovarian adenocarcinoma. It is HER2-positive, making it relevant for targeted therapy studies. SK-OV-3 is widely applied in ovarian cancer drug discovery. Its reproducibility makes it a standard preclinical model.
Key Features:
- Derived from ovarian adenocarcinoma.
- HER2-positive ovarian cancer line.
- Aggressive xenograft growth.
- Epithelial carcinoma morphology.
Applications:
SK-OV-3 supports targeted therapy research for ovarian cancer. It is used in biomarker validation and drug resistance studies. Researchers apply it in preclinical screening programs. Its HER2 positivity provides translational value for therapy development.
Details
- Tumor indication
- Ovarian, Fallopian Tube
- Tumor subtype
- Serous carcinoma of the ovary
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- Proteomics, RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Lumin data
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.